First generation leishmaniasis vaccines: A review of field efficacy trials

被引:138
作者
Noazin, Sassan [1 ]
Modabber, Farrokh [2 ,7 ]
Khamesipour, Ali [2 ]
Smith, Peter G. [3 ]
Moulton, Lawrence H. [4 ]
Nasseri, Kiumarss [5 ]
Sharifi, Iraj [6 ]
Khalil, Eltahir A. G. [7 ]
Bernal, Ivan Dario Velez [8 ]
Antunes, Carlos M. F. [9 ]
Kieny, Marie Paule [1 ]
Tanner, Marcel [10 ]
机构
[1] WHO, CH-1211 Geneva 27, Switzerland
[2] Univ Tehran Med Sci, Ctr Res & Training Skin Dis & Leprosy, Tehran 141556383, Iran
[3] Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, London WC1E 7HT, England
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA
[5] Calif Canc Registry, Inst Publ Hlth, Santa Barbara, CA 93105 USA
[6] Kerman Univ Med Sci, Leishmaniasis Res Ctr, Kerman, Iran
[7] Univ Khartoum, Inst Endem Dis, Khartoum, Sudan
[8] Univ Antioquia, PECET, Programa Estud & Control Enfermedades Trop, Medellin, Colombia
[9] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Parasitol, BR-31270901 Belo Horizonte, MG, Brazil
[10] Swiss Trop Inst, Dept Epidemiol & Publ Hlth, CH-4002 Basel, Switzerland
基金
英国医学研究理事会;
关键词
Leishmaniasis; Vaccine; Clinical trial; Review;
D O I
10.1016/j.vaccine.2008.09.085
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
First generation candidate vaccines against leishmaniasis, prepared using inactivated whole parasites as their main ingredient, were considered as promising because of their relative ease of production and low cost. These vaccines have been the subject of many investigations over several decades and are the only leishmaniasis vaccine candidates which have undergone phase 3 clinical trial evaluation. Although the studies demonstrated the safety of the vaccines and several studies showed reasonable immunogenicity and some indication of protection, an efficacious prophylactic vaccine is yet to be identified. Despite this overall failure, these trials contributed significantly to increasing knowledge on human leishmaniasis immunology. To provide a collective view, this review discusses the methods and findings of field efficacy trials of first generation leishmaniasis vaccine clinical trials conducted in the Old and New Worlds. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6759 / 6767
页数:9
相关论文
共 57 条
  • [1] Visceral leishmaniasis: Consequences of a neglected disease in a Bangladeshi community
    Ahluwalia, IB
    Bern, C
    Costa, C
    Akter, T
    Chowdhury, R
    Ali, M
    Alam, D
    Kenah, E
    Amann, J
    Islam, M
    Wagatsuma, Y
    Haque, R
    Breiman, RF
    Maguire, JH
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2003, 69 (06) : 624 - 628
  • [2] The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis
    Alimohammadian, MH
    Khamesipour, A
    Darabi, H
    Firooz, A
    Malekzadeh, S
    Bahonar, A
    Dowlati, Y
    Modabber, F
    [J]. VACCINE, 2002, 21 (3-4) : 174 - 180
  • [3] CONTROLLED FIELD TRIALS OF A VACCINE AGAINST NEW-WORLD CUTANEOUS LEISHMANIASIS
    ANTUNES, CM
    MAYRINK, W
    MAGALHAES, PA
    COSTA, CA
    MELO, MN
    DIAS, M
    MICHALICK, MSM
    WILLIAMS, P
    LIMA, AO
    VIEIRA, JBF
    SCHETTINI, APM
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1986, 15 (04) : 572 - 580
  • [4] Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: Safety, immunogenicity, and efficacy during the first 12 months of follow-up
    Armijos, RX
    Weigel, MM
    Aviles, H
    Maldonado, R
    Racines, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (05) : 1352 - 1357
  • [5] Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis
    Armijos, RX
    Weigel, MM
    Calvopina, M
    Hidalgo, A
    Cevallos, W
    Correa, J
    [J]. VACCINE, 2004, 22 (9-10) : 1320 - 1326
  • [6] Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: How long does protection last?
    Armijos, RX
    Weigel, MM
    Romero, L
    Garcia, V
    Salazar, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (12) : 1959 - 1961
  • [7] Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers
    Bahar, K
    Dowlati, Y
    Shidani, B
    Alimohammadian, MH
    Khamesipour, A
    Ehsasi, S
    HashemiFesharki, R
    AleAgha, S
    Modabber, F
    [J]. CLINICS IN DERMATOLOGY, 1996, 14 (05) : 489 - 495
  • [8] The predictive validity of naturally acquired delayed-type hypersensitivity to leishmanin in resistance to Leishmania major-associated cutaneous leishmaniasis
    Ben Salah, A
    Louzir, H
    Chlif, S
    Mokni, M
    Zaâtour, A
    Raouène, M
    Ben Ismaïl, R
    Dellagi, K
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (11) : 1981 - 1987
  • [9] A policy for leishmaniasis with respect to the prevention and control of drug resistance
    Bryceson, A
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2001, 6 (11) : 928 - 934
  • [10] CABRERA MT, 1994, CELL RESPONSES ASS I